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New forms of aid, including “philanthrocapitalism” such as The Bill and Melinda 
Gates  Foundation,  are  rapidly  altering  the  international  aid  architecture  for 
health. These organisations have financial power, actively shape agendas and 
influence  policy.  The  rise  of  non‐traditional  donor  organisations  creates 
opportunities and has implications for Australia as it scales‐up its aid program. 
AusAID  could  collaborate,  complement,  compete  with,  or  copy  these 
organisations.  Arguably  the  biggest  strategic  implication  is  that  they  expand 
AusAID’s  programming  choices.  This  increased  flexibility  could  be  used  to 
leverage and accelerate further reforms in the UN and elsewhere. But choice is a 
two way street. Developing countries may prefer large, grant financing from non‐
traditional aid organisations and choose to bypass traditional multilateral and 
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The Bill and Melinda Gates Foundation: business versus bureaucracy in 
international development 
1.  Purpose and scope of this paper 
The ‘aid architecture’ for international health is rapidly changing. Several large non–
traditional organisations have emerged in recent years: the Global Fund to Fight AIDS 
Tuberculosis and Malaria (GFATM); the Global Alliance for Vaccines and Immunisation 
(GAVI); the Bill and Melinda Gates Foundation and the Clinton Foundation. These new 
organisations are increasingly shaping the international health agenda as well as the 
level and direction of resource flows. This paper takes the global health program of one 
such non‐traditional organisation that scaled up rapidly – the Bill and Melinda Gates 
Foundation – to identify possible lessons and implications for Australia as it continues to 
double its aid program.  
2. The Bill and Melinda Gates Foundation in context 
International development assistance for health has grown noticeably over recent years, 
with  an  increasing  share  coming  from  or  coursed  through  new,  non‐traditional 
institutions. In an important study published in The Lancet – and funded from a research 
grant of the Bill and Melinda Gates Foundation – Ravishankar and colleagues track the 
trends  (Ravishankar  et  al.  2009).  They  find  that  global  development  assistance  for 
health grew from $US 5.6 billion in 1990 to $US 21.8 billion by 2007. The proportion of 
funding coursed through UN agencies – UNICEF, UNFPA, WHO etc. – fell over that period 
from 32% to 14%. Funding through the World Bank and regional development banks 
fell from a peak of 21% in 2000 to 7.2% by 2007. Funding through bilateral agencies fell 
from 46.8% in 1990 to 27% in 2001, rising to 34% in 2007.  
Much of the squeeze in relative contributions is explained by the rapid emergence of 
new, non‐traditional financing organisations for international health. GFATM, GAVI, and 
BMGF grew from less than 1% of international development assistance for health in 
1990  to  8.3%,  4.2%,  and  3.9%  respectively.  Business  philanthropies  that  support 
international development are not new. The Rockefeller Foundation has been operating 
since 1913. It has provided a cumulative total of more than $US 14 billion in current 
dollar and claims to have provided more foreign aid than the United States Government 2 
 
up until World War Two (Rockefeller Foundation 2009). It has been a strong supporter 
of the “Green Revolution”. Similarly, The Ford Foundation has been active since 1936. It 
approved $US 490 million worth of programs in 2009, including $US20 million to South 
Asia, $US 16 million to both China and South Africa, and $US 32.6 million for sexual and 
reproductive health. 
What is new is the scale and reach of the new “philanthrocapitalism” typified by the Bill 
and  Melinda  Gates  Foundation  (BMGF).  Total  grant  commitments  since  inception  of 
BMGF in 1994 to March 2011 now total $US 24.8 billion. The Asset Trust Endowment is 
$US 37.1 billion. Grant payments totalled $US 2.6 billion  in 2010. Grants have been 
provided  to  over  100  countries,  and  each  of  the  50  states  within  the  US.  One 
commentator notes that:  
“At the end of 2005, the Gates Foundation endowment stood at $ US 35 billion, 
making it the largest  in the world. Then  in June 2006, Warren  E. Buffett, the 
world's second‐richest man after Bill Gates, pledged to add about $US 31 billion 
in installments from his personal fortune. Not counting tens of billions of dollars 
more that Gates himself has promised, the total is higher than the gross domestic 
products of 70% of the world's nations.” (Piller et al. 2007) 
The single largest area of investment is Global Health: $US 14.4 billion (58%) of total 
commitments between 1994 and March 2011.1  A review in The Lancet concluded that: 
“In 2007, the amount spent by the Gates Foundation on global health was almost 
as  much  as  WHO’s  annual  budget  (approximately  $1.65  billion),  and  was 
substantially more than the total grant spending of the Rockefeller Foundation 
across  all  programmatic  areas  in  the  same  year  ($0·17  billion).  The  Gates 
Foundation’s effect on global health is evident in malaria research. In the late 
1990s, only $84 million was spent on malaria research yearly; since 2000, the 
Gates Foundation has helped to roughly treble this amount.” (McCoy et al. 2009) 
                                                        
 
1  BMGF  are  also  large  and  important  funders  of  broader  development  goals  including  agricultural 
development, microfinance, and, in the United States, education programs. However, Global Health is the 
major activity. 3 
 
However even the largest organisations need to be seen in context. An influential article 
in The Lancet notes that the four largest contributors to international health – the World 
Bank, BMGF, US Government and GFATM  –  together account for around 0.1% of all 
health expenditures in non OECD countries (Sridhar & Batniji 2008). Indeed all donors 
combined  still  account  for  only  around  0.3%  of  total  expenditures  on  global 
development health. In India, total external resources for health were just 1.4% of total 
expenditure  on  health  (WHO,  2010).  Nevertheless,  donors  can  still  wield 
disproportionate influence on policy and programs: witness the long standing debate in 
international health circles about whether donor funding for HIV and AIDS distorts, or 
supports, national health programs. Country context matters. 
3. Key Global Health Operations of BMGF 
BMGF concisely describe their work to support Global Health as follows: 
“Our work in infectious diseases focuses on developing ways to fight and prevent 
enteric and diarrheal diseases, HIV/AIDS, malaria, pneumonia, tuberculosis, and 
neglected  and  other  infectious  diseases.  We  also  work  on  integrated  health 
solutions  for  family  planning,  nutrition,  maternal,  neonatal  and  child  health, 
tobacco control and vaccine‐preventable diseases. Three cross‐cutting programs 
help us successfully address our areas of focus. These include: 
  Discovery – Closing gaps in knowledge and science and creating critical 
platform technologies in areas where current tools are lacking. 
  Delivery – implementing and scaling up proven approaches by identifying 
and proactively addressing the obstacles that typically lie in the path of 
adoption and uptake 
  Policy  &  Advocacy–  Promoting  more  and  better  resources,  effective 
policies, and greater visibility of global health so that we may effectively 
address the foundation’s priority health targets” (Gates Foundation 2011) 
4. How BMGF scaled up 
BMGF were able to scale up their program, and their profile, in such a relatively short 
time for three reasons. 4 
 
First, having decided that global health would be a priority for them, they then had the 
means, motive, and opportunity to ‘think big’ right from the start. Second, the Gates 
profile and financial strength meant they could bring in, off the shelf, a critical mass of 
highly  paid2  technical  expertise  to  develop  their  own  strategies,  and  make  an 
international  presence.  This  included  bringing  in  several  people  with  already 
international reputations for technical expertise. It was the combination of money, the 
Gates name, and a pool of internationally credible technical expertise that opened doors 
internationally and let BMGF move fast. Third, and most importantly, BMGF deliberately 
chose  to  be  “funders  and  shapers…we  rely on  others  to  act  and  implement”.3  Thus, 
BMGF provided $US 1.5 billion to the Global Alliance for Vaccines and Immunisation. 
Providing  large  tranches  to  existing,  compatible,  agencies  enabled  rapid  scale  up  of 
activities. 
However BMGF are certainly not just ‘hands off’ funders that simply outsource global 
health  work  to  other  organisations.  Instead,  BMGF  engage  actively  in  international 
debates that, in turn, affect global aid flows.4 BMGF also engage directly, and indirectly, 
in the management of major institutions supporting global health, and actively seek to 
shape their agendas. This is something of a mixed blessing. Participation by BMGF brings 
a welcome sense of urgency, respect for evidence, commercial nous, and a cap acity for 
quick financial follow up to international meetings. But private power and high profile of 
a foundation like BMGF has risks too. As one thoughtful analysis in The Lancet finds: 
“All  the  key  contributors  to global  health  have  an  association  with  the  Gates 
Foundation through some sort of funding arrangement. Coupled with the large 
amount of money involved, these relations give the foundation a great degree of 
                                                        
 
2  Compensation  of  $US  2.627 million was  paid  to  the  five  highest  paid  employees  of  BMGF  in  2009. 
(Reference: Readers Guide to the form 990 PF. Available at www.gatesfoundation.org.     
3 BMGF Guiding principle number four. 
4 In his latest annual newsletter, Bill Gates worries that large fiscal deficits in OECD countries will squeeze 
aid programs. He says: “Deficits are not the only reason that aid budgets might change. Governments will 
also be increasing the money they spend to help reduce global warming. The final communiqué of the 
Copenhagen Summit, held last December, talks about mobilizing $10 billion per year in the next three 
years and $100 billion per year by 2020 for developing countries, which is over three quarters of all 
foreign aid now given by the richest countries. I am concerned that some of this money will come from 
reducing other categories of foreign aid, especially health. If just 1 per cent of the $100 billion goal came 
from vaccine funding, then 700,000 more children could die from preventable diseases. In the long run, 
not spending on health is a bad deal for the environment because improvements in health, including 
voluntary family planning, lead people to have smaller families, which in turn reduces the strain on the 
environment”. 5 
 
influence over both the architecture and policy agenda of global health. Through 
its  funding  of  non‐governmental  organisations  and  policy  think  tanks,  the 
foundation  also  confers  power  and  influence  on  a  selected  number  of 
organisations and in doing so, establishes some leverage over the voice of civil 
society. These observations are pertinent because the Gates Foundation is not a 
passive  donor.  The  foundation  actively  engages  in  policy  making  and  agenda 
setting activities; it has representatives that sit on the governing structures of 
many global health partnerships; it is part of a self‐appointed group of global 
health  leaders  known  as  the  H8  (together  with  WHO,  the  World  Bank,  GAVI 
Alliance,  the  Global  Fund,  UNICEF,  the  United  Nations  Population  Fund,  and 
UNAIDS); and has been involved in setting the health agenda for the G8.” (McCoy 
et al. 2009) 
The Gates Foundation is also involved in setting the research agenda of several public 
health priorities, a role that was controversially criticised by the former head of WHO’s 
malaria programme, who complained that the dominance of the Gates Foundation in 
malaria research risked stifling the diversity of views among scientists. 
5. Strengths and Weaknesses of BMGF 
BMGF has five main strengths, listed below in what I see as their order of significance. 
1.  They  invest  cleverly  in  rigorous  operational  research  that  shapes  broader, 
strategic, evidenced based policy and resource flows by governments and their 
development partners. Development partners speak warmly and often about the 
need for evidenced based policy in global health. But few actually invest in it. 
BMGF  have  funded  numerous,  large,  operationally  relevant  field  studies  in 
developing countries.5 The underlying rigour, including funding of randomised 
control trials, and consideration of the counter  –  factual,  provides  a  strong 
evidence base for subsequent policy making. Rigorous but relevant results then 
                                                        
 
5 For example BMGF were sole, major, or contributing, funders to the following applied research, many of 
which involved randomised control trials: ‘Oral Misoprostol in preventing postpartum haemorrhage in 
resource‐poor communities: a randomised controlled trial’ (Derman et al. 2006); ‘Evidence based, cost 
effective interventions: how many newborn babies can we save?’ (Darmstadt et al. 2005); ‘Implementing 
community‐based perinatal care: results from a pilot study in rural Pakistan’ (Bhutta et al. 2008). 6 
 
have  the  potential  to  influence  not  just  the  resourcing  and  approaches  of  all 
development partners but – more importantly – the developing country’s overall 
health budget. This is arguably BMGF’s greatest and most strategic contribution 
to international development. Generating ‐ and disseminating ‐ usable evidence 
for policy in influential journals like The Lancet is taken seriously by BMGF. BMGF 
are also investing in the Malaria Control and Evaluation Partnership in Africa 
(MACEPA) and are part of the Alliance for Case Studies in Global Health. There 
are now 139 separate evaluation reports on the BMGF website.6 
2.   They  invest,  at  scale,  in  evidenced‐based  but  underfunded  interventions, 
including vaccines. This is what they are most well known for. For example, they 
provided $US 1.5 billion to the Global Alliance for Vaccines and Immunisation. 
They also invest in response to neglected diseases.7 
3.  They “crowd in” additional, or expand existing, private finance for international 
development. Warren Buffett has provided $US 8.01 billion to BMGF: arguably 
money that may not have gone to international development otherwise. BMGF 
has itself expanded other private ventures: for example, joining a $US 500 million 
program  with  the  Bloomberg  Initiative  to  reduce  the  tobacco  epidemic  in 
developing countries. 
4.  They  take  bold,  but  calculated,  investment  risks.  Their  “Grand  Challenges” 
program  has  supported  over  400  high  risk  /  high  impact  research  grants  to 
encourage innovation.8 At the policy level, BMGF has invested $US125 million to 
fight the tobacco epidemic: a high impact initiative in health, but with high risks 
given the complex policy environment of tobacco production in China. 
5.  They bring a sense of urgency, and efficiency, to the table. 
There are, of course, criticisms of the BMGF. Importantly, many such criticisms are not 
unique to BMGF, and can apply to most if not all organisations involved in global health. 
The more important claims are summarised below:9 
                                                        
 
6http://www.gatesfoundation.org/Pages/Search.aspx?meta=MDContentType:Research%26Evaluation.  
7 Further details available at http://www.gatesfoundation.org/topics/Pages/neglecteddiseases.aspx.  
8 For example, testing a smart phone that can verify drug compliance in a patient and then  reward the 
person by allocating free extra phone credits. 
9  Including criticism  that  the  BMGF  endowment  invests  in  companies  that  harm  the  environment  in 
developing countries. (see Piller et al. 2007). 7 
 
The funding potentially distorts priorities by focusing on a few high profile diseases, 
thereby draining resources from other needs of concern to the poor. One study found 
that  the  ‘big  four’10  10  funders  of  global  health,  including  BMGF,  allocated  funding 
equivalent  to  $US  1029  for  every  death  arising  from  HIV  AIDS  (Sridhar  and  Batniji 
2008).  However,  the  big  four  provided  much  less  for  other  causes  that 
disproportionately affect the poor: $US 20.3 for every death arising from malnutrition, 
and just  $US 3.2 per death from non‐ communicable diseases. (See, however, above 
comment about BMGF funding for neglected diseases). 
Interventions focus too much on technological fixes, whereas management, governance, 
and cultural issues are key determinants for health in developing countries. A common 
criticism is that a preference for science based technical solutions overlooks the need for 
broader health system strengthening.  
Grants favour US and OECD based institutions. One careful study of BMGF grant making 
in The Lancet found that  
“of the 659 grants awarded to non‐governmental or non‐profit organisations, 560 
went to organisations in high‐income countries, primarily in the USA. Only 37 
grants were made to non‐governmental or non‐profit organisations based in low‐
income and middle‐income countries.” (McCoy et al. 2009) 
The  overall  grant  making  process  lacks  transparency.  An  independent  evaluation11 
commissioned  of  grantees  by   BMGF  found  that  BMGF  had  lower  ratings  than 
comparable organisations in terms of  clarity of goals, transparency, and consistency of 
decision making. Staff turnover was a source of complaint too. 
6. Some implications for AusAID as it scales up. 
Appendix Two summarises some of the interesting similarities and differences between 
AusAID and BMGF.  
                                                        
 
10 World Bank, US Government, GFATM, and BMGF. 
11 Center for Effective Philanthropy: Details of the evaluation available at www.gatesfoundation.org.  8 
 
One implication from that table is that AusAID could collaborate, complement, compete 
with or copy the BMGF approach, depending upon the circumstances.  
Collaboration can – and has – occurred between BMGF and AusAID in program areas of 
common concern, such as maternal and child health. Collaboration has also occurred in 
knowledge generation. For example, AusAID, BMGF, and the University of Queensland 
collaborated in estimating the costs of scaling up proven interventions for maternal and 
child  health  in  Asia.  Arguably,  the  combination  of  these  three  institutions  working 
together magnified the profile and reach of the work much more so than if each had 
acted separately. 
AusAID and BMGF can also complement each other’s strengths. AusAID has excellent, 
ongoing, access to key Government policy makers throughout Asia and the Pacific; is 
experienced in service delivery; has professional and experienced staff posted across the 
Asia  and  Pacific;  and  has  a  scholarships  program  that  builds  capacity.  BMGF  has 
excellent access to scientific research in health; has convening power amongst many 
stakeholders including the private sector; and is deeply and widely engaged in Africa. 
However, in some circumstances, AusAID and BMGF may be competitors. Both are grant, 
untied, financiers chasing viable development opportunities. Both wish to recruit good, 
experienced, international and local talent. Both operate in the same sectors in the same 
countries:  potentially  with  quite  different  policy  advice  to  Government.  BMGF  are 
increasingly likely to win policy debates at the country level, at the expense of AusAID 
views, unless AusAID continues to build up its own in – house technical expertise, and 
invest more in operational research. Both BMGF and AusAID are also likely to compete 
for influence and ideas on the boards of international organisations. 
AusAID could also copy some of the BMGF approaches, particularly the emphasis given 
by  BMGF  to  rigorous  operational  research.  Access  to  finance  is  rarely  the  binding 
constraint to development in fast growing Asia or the aid supported Pacific, but access to 
useful and usable knowledge is. Developing countries often know what to do, but are 
less sure about how to do it in their own country circumstances. Consultancy based 
advice  is  no  substitute  for  field  based  operational  research  and  assessment  of  the 
counter – factual. 9 
 
BMGF have invested heavily, and strategically, in field experiments that yield rigorous 
results, exploring the counter – factual, that can then form an evidence base for shaping 
policy. They fund top class research institutions to undertake ethical, randomised, or 
quasi experimental, interventions and invest heavily in collecting and interpreting the 
data. They then fund dissemination of peer reviewed results in high impact journals 
such  as  The  Lancet.  AusAID  could  and  should  copy  this  commitment  to  operational 
research, especially as it scales up itself. There are good, sound, practical approaches 
available to draw on.12 
Perhaps the most strategic implication for Au sAID is the  competition that BMGF and 
similar organisations introduce into the international aid architecture. Twenty or thirty 
years ago, Australia’s choices for allocating large sums of ODA were limited to the World 
Bank,  the  Asian  Development  Bank,  and  certain  UN  agencies.  Importantly,  those 
agencies knew that there were reasonably limited choices available for Australia too. 
Threats by Australia to reallocate or reduce funding unless those organisations stepped 
up their reform agendas were seen as just that: threats. These days, Australia and other 
development  partners  are  under  even  sharper  scrutiny  to  demonstrate  “results” 
including from the multilaterals and UN. 
But  Australia  and  other  development  partners  now  have  real  options,  especially  in 
international health where non  – traditional institutions are increasingly present. In 
principle, part of Australia’s rapid scale up of funding could just as easily go to GFATM, 
GAVI, Clinton  Foundation, or BMGF as it could to the multilaterals and UN.  Just  the 
availability  of  those  new  options  therefore  gives  Australia  enhanced,  credible, 
negotiating coin in its replenishment negotiations with the multilaterals and the UN. If 
they don’t pursue their reform agendas as purposefully as they claim they will, some of 
the  additional  “new”  money  from  Australia’s  scale  up  will  go  to  the  new,  non  – 
traditional agencies. Strengthening the hand of reformers within the large multilaterals 
and UN may turn out to be one of the more strategic impacts of an expanding Australian 
aid program, if coupled with the exercise of expanded choice. 
                                                        
 
12 For example: Duflo 2004, Duflo & Kremer 2003, Clemens & Demombynes 2010. 10 
 
Ironically, the very competition that Australia could use to push reforms could be used 
against  it.  The  existence  of  large,  untied,  grant  financing  for  rapid  expansion  of  an 
immunisation  program,  sourced  ultimately  from  BMGF,  is  an  attractive  option  for  a 
developing  country  government.  It  may  well  be  seen  as  preferable  in  some 
circumstances  to  the  alternative  of  Australian  sponsored  “policy  dialogue”  about 
governance and corruption. That would especially be the case if Australia was unable to 
consistently  ground  its  policy  dialogue  in  health  on  a  strong  evidenced  base  of 
operational research and deep technical expertise as BMGF do. 
7. Conclusion 
The international environment – especially for health – is rapidly changing. Standing still 
is to be left behind, less and less able to influence global health events that will affect 
developing  countries,  as  well  as  Australia.  Australia’s  decision  to  scale  up  its 
development assistance program is a sound investment in the future, especially in an 
increasingly inter‐connected world. Making good choices – including how to best work 
with  relatively  new,  but  influential,  institutions  such  as  the  Bill  and  Melinda  Gates 












8. Appendix 1: Engagement of the Bill and Melinda Gates Foundation 
in International Health 
 
Source: Ravishankar N et al “Financing of Global Health: Tracking Development Assistance for Health from 







Source: Ravishankar N et al “Financing of Global Health: Tracking Development Assistance for Health from 






9. Appendix 2 
Theme  AusAID  BMGF 
Goal setting  Reflects Australian Government national interest priorities, and 
partner government requests 
“This is a family foundation, driven by the interests and 
passions of the Gates family”. 
13 
Specific goal setting influenced by science 
Accountability 
and scrutiny 
Minister, Parliament, and public (eg via FOI Act).   Board, Annual Report, Ethical code, whistle-blower policy 
etc.  
Subject to various Acts and regulations  including Finance, 
Procurement, Employment, Freedom of Information Act, etc. 
“We take risks, make big bets, and move with urgency.   
We are in it for the long haul.” 
14 
Focus  Several sectors, including governance, education and health   Global health a priority.   
Focus on Asia and the Pacific  Active in over 100 countries and every state in the USA 
Financing  Subject to annual appropriations. 100% grant, untied, in yearly 
appropriations 
Endowment size affected by stock market.  100% grant, 
untied, but long multi - year commitments possible 
Operations  Direct access to highest levels of Government in developing 
countries. 
Strong credibility and convening power  amongst private 
sector 
In country delivery, often using AusAID staff and/or consultants, 
often 3 – 5 year time frame.   
Use, at least historically, of managing contractor firms, 
consultants, and advisers to government 
“We are funders and shapers. We rely on others to act and 
implement”. 
15 
Typically grant funding to another body (eg GAVI) or 
research institute, often long time frame 
Actively engages in the  policy and programming of IFIs, UN and 
MDB 
Actively engages in the  policy and programming of IFIs, UN 
and MDB 
“Knowledge” and evidence base increasingly important: 
“knowledge hubs” and research grants gaining profile.  
Latest evidence drives decision making.  If important 
evidence not available, invest heavily in creating it 
Risk of fragmentation of effort.  See AusAID ARDE 2009.  Risk of fragmentation of effort: 1094 global health grants 
were awarded between January, 1998, and December, 
2007 
  Strong emphasis on research institutions and Universities 
Size and 
staffing 
$A 4.3 billion in 2010/11. Good, but limited number, of in-house 
people with up to date technical expertise.   Relatively limited 
career stream based around technical expertise. 
$US 3 billion grant approvals in 2009.  874 staff, mainly 
technical specialists.  Strong in – house technical expertise, 
some of which is world class. 
At 30 June 2010, AusAID had 1487 staff: 1004 were Australian 
Public Service employees, and 483 were “Overseas Based Staff” 
(often local nationals).   
BMGF has approximately 927employees in March 2011.   
AusAID Departmental Expenses were $134 million in 2009/10.  
Employee benefits were $86.5 million in 2010.   
Compensation of $US 2.627 million was paid to the five 




                                                        
 
13 Guiding Principles of the Bill and Melinda Gates Foundation.  This is the first Guiding Principle.  The 
fifteen  Guiding  Principles  are  available  at  http://www.gatesfoundation.org/about/Pages/guiding-
principles.aspx.     
14 Guiding Principle Number 7. 
15 Guiding Principle Number 4. 14 
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